joint Protein Central

Therapeutic Areas

Drug developments are made through strategic alliances, collaborations, and partnerships with pharmaceutical companies. The first drug in our pipeline, AB204, originated from protein engineering research conducted at the joint Center for Biosciences, an academic research institute founded in 2008 by a long-time Salk Institute resident faculty member, Professor Senyon Choe of University of California, San Diego. Dr. Choe's major honors include his election in 1999 to the Fellow of American Association for the Advancement of Science. JPC's pipeline spans across multiple therapeutic areas from cancer, bone, cartilage, fibrosis to metabolic disorders. JPC's research investment focuses on protein engineering of TGF-beta superfamily ligands and developing new stem cell therapy. An extension of the research explores designing synthetic biologics (chimera) to modulate stem cells and sick cells directly.